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Epirubicin chemotherapy in women with breast cancer: alternating arms for 
intravenous administration to reduce chemical phlebitis. 
 
Abstract:   
Objective; To establish whether using alternating arms for peripheral intravenous epirubicin 
administration affects the severity or duration of epirubicin-induced phlebitis.  
Methods; An observational study of females with breast cancer (n= 237) in a UK Cancer 
Centre. Data were analysed after receiving 3 treatment cycles according to the arm used for 
epirubicin administration: same, alternating, or mixed arm (2 consecutive cycles in one arm, 
one in the alternate arm). Phlebitis severity was graded by clinical staff after each 
treatment, participants also self-reported symptoms during treatment and for up to 6 
months after.  
Results: The alternating arms group experienced significantly less severe symptoms than the 
other arm use groups, 6% (4 of 64) compared to 34% (p <0.001, odds ratio: 0.13 (95% CI: 
0.043- 0.38) alternating arm compared to same arm group). The alternating arm group 
reported less pain (p=0.013), lower overall impact (p= 0.009) lower effect on function (p= 
0.032) and shorter duration of symptoms (p=0.001) than the other arm use groups.  
Conclusion: Using alternating arms for peripheral administration of epirubicin significantly 
reduces the severity and duration of chemical phlebitis and is recommended to improve 
patient experience and reduce the need for central venous access devices.  
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Introduction:  
Breast cancer is the most frequently occurring cancer in women, affecting 2.1 million 
women worldwide each year (Bray et al 2018). In the UK breast cancer accounts for nearly a 
third of female cancers (Cancer Research UK, 2018) and approximately 34% of women with 
a primary diagnosis of invasive breast cancer will receive intravenous chemotherapy 
treatment (Cancer Research UK, 2018). Many will receive treatment with a combination of 
chemotherapy drugs including an anthracycline (such as epirubicin) as recommended by the 
National Institute for Health and Care Excellence Guidelines (NICE, 2018).  
Epirubicin chemotherapy is known to cause phlebitis and venous sclerosis when 
administered through a peripheral cannula (Yamada et al, 2012). The reported incidence of 
epirubicin induced phlebitis varies considerably from 15 – 89% (Nagata et al, 2012; Lennan 
et al 2005) Phlebitis is defined as inflammation of a vein (Royal College of Nursing (RCN), 
2016) and can be the consequence of chemical, mechanical or bacterial irritation of the 
tunica intima (Higginson and Parry, 2011). The phlebitis caused by epirubicin chemotherapy 
is due to chemical irritation and can result in a variety of symptoms including pain, arm 
tightness, swelling, redness, (Marshall-McKenna et al. 2015) and even puckering of the skin 
caused by sclerosis of the veins (Bolton-Maggs and Flavin 2005). These symptoms can last 
for more than 3 months post chemotherapy resulting in a considerable impact on the 
patient’s quality of life and their ability to perform normal daily activities (Marshall-
Mckenna et al. 2015). Furthermore, epirubicin is frequently administered in multi-drug 
combination chemotherapy regimens including 5-fluorouracil which can also 
cause phlebitis.  
Concerns about the debilitating effect of phlebitis has resulted in the decision in at least one 
UK cancer centre to use peripherally inserted central venous catheters for all anthracycline 
chemotherapy (Harrold et al. 2015). This is currently not routine practice across the UK 
because of the small, but potentially serious complications of thrombosis and sepsis 
associated with central lines (LaRue and Peterson 2011, Gabriel 2013) as well as the 
significant financial and service implications.  
It has been widely accepted practice for breast cancer patients following surgery to use the 
contralateral arm for all intravenous treatments. The rationale for avoiding venepuncture 
and cannulation of the ipsilateral arm following breast surgery is that it is thought to reduce 
the risk of developing lymphoedema. However, recent reviews have concluded that there is 
no convincing evidence for avoiding cannulation of the ipsilateral arm (Ferguson et al 2016, 
Jakes and Twelves 2015). The practice of repeated cannulation in the same arm has been 
shown by Uslusoy and Mete (2008) to increase the risk of phlebitis for surgical inpatients, 
but to date there are no reported studies looking specifically at patients receiving 
chemotherapy for breast cancer.  
Following a review of the literature (Ferguson et al 2016; Jakes and Twelves 2015; Lennan 
and Richardson 2015; Cemal et al 2011) and consultation with the local lymphoedema 
specialist nurse a decision was made by the clinical team at Velindre Cancer Centre to 
recommend using alternate arms for chemotherapy administration in patients who had not 
undergone a full axillary node clearance. It was anticipated that alternating arms would 
reduce the incidence and severity of phlebitis in patients receiving combination 
chemotherapy including epirubicin at 3-weekly intervals.   
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The aim of this study was to establish if alternating the arm used for intravenous epirubicin 
administration over 3 cycles of chemotherapy would affect the severity or duration of 
epirubicin-induced phlebitis.  
Methods:  
A prospective observational study was used to collect clinical staff and participant 
assessments of phlebitis symptom severity following three cycles of chemotherapy 
containing epirubicin administered at 3-weekly intervals.   
The study population comprised women with breast cancer receiving combination 
chemotherapy including epirubicin (Table 1) via a peripheral cannula (for inclusion and 
exclusion criteria see Table 6).  Participants were recruited from Velindre Cancer Centre, 
Cardiff between May 2016 and January 2018, and from Aneurin Bevan University Health 
Board, South East Wales between October 2016 and November 2017. Participants in both 
locations were treated by Velindre Cancer Centre nursing staff following the Cancer Centre 
guidelines. Chemotherapy was administered through a 24g cannula for all participants and 
epirubicin was administered by experienced chemotherapy nurses as a bolus into the 
injection port on the tubing of a free running intravenous infusion of 0.9% saline. The study 
received local ethical approval (REC reference: 16/WA/0074) and written informed consent 
was obtained from all participants.  Participant characteristics and treatment-related 
information was collected from medical records and a baseline participant questionnaire.  
Following the Cancer Centre guidelines participants who had undergone a sentinel node 
biopsy (SNB), or were receiving neo-adjuvant chemotherapy prior to surgery, were free to 
choose (after discussion with the clinical team) which arm, or combination of arms to use 
for chemotherapy administration. There was no imposed randomisation of arm to use, or 
control of which arm (the ipsilateral or contralateral) to use first. Following local guidelines 
those who had undergone an axillary node clearance (ANC) were advised to only use the 
contralateral arm for chemotherapy. 
Participants could be divided into five groups according to the sequence of arm chosen for 
epirubicin administration. The possible sequences of arm used over 3 cycles were 1) same 
arm for each treatment due to ANC; 2) same arm without ANC; 3) alternating arms; 4) first 2 
cycles in one arm then the 3rd cycle in the alternate arm and 5) first cycle given in one arm 
followed by 2 cycles in the alternate arm 
A chemotherapy phlebitis severity assessment tool developed by Velindre Cancer Centre 
with an inter-rater reliability of 89% was used to grade symptoms from 0 (no symptoms) to 
4 (severe symptoms) (Figure 1). Assessments were performed by clinical staff at the 
chemotherapy clinic review approximately 3 weeks post treatment. After each treatment 
cycle participants were asked to complete a short questionnaire (see supporting 
information) designed to allow self-reporting of the severity and impact of any symptoms 
experienced.   
Participants also completed a follow up self- assessment questionnaire once every 3-4 
weeks if they still had symptoms on completion of epirubicin chemotherapy. The 
questionnaire was completed either face to face, by telephone or on-line depending on 
patient preference and whether they had a pre-planned hospital attendance.   
.  
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A Chi Square test was used to identify differences between groups. Statistical significance 
was set at 0.05. Statistical Package for Social Science V25 (USA) software was used to make 
the comparisons.  
Results:   
Participant characteristics and arm use groups   
Complete data for three cycles was collected from 90% (237 of 263) of the women recruited 
with a mean age of 54 (±10) and a mean BMI of 29 (±6).  214 (90%) were Caucasian, 134 
(10%) participants described themselves as current smokers, 79 (33%) as previous smokers 
and 134 (57%) had never smoked. 147 participants (62%) received 75mg/m2 of epirubicin, 
85 (36%) received 100mg/m2 and 5 (2%) 60mg/m2 (Table 2). Assessment data were not 
complete for 2 women, and 24 did not receive three cycles of epirubicin peripherally; of 
these 4 continued treatment with a central venous catheter, epirubicin was stopped after 
cycle 1 for two participants and after cycle 2 for the remaining 18.  
There was no significant difference (p = 0.51) in the severity of symptoms experienced 
between the two same arm groups (ANC and non-ANC) so they were combined to form a 
single group (Group1, Table 2). Forty six percent (108 of 237) of the participants received all 
three cycles of chemotherapy in the same arm. Alternating arms were used in 64 (27%) 
cases. No significant difference (p = 0.59) could be demonstrated between sequences 4 and 
5 so they were also combined as the mixed arm use group, 65 (27%) received two 
consecutive cycles in one arm and one cycle in the alternate arm (Group 3, Table 2).  
No differences in the dose of epirubicin or key baseline characteristics other than a 
significant difference in axillary surgery between the same arm group (Group 1, Table 2) and 
the other arm use groups (Groups 2 and 3, Table 2) were noted.  The higher proportion of 
participants in Group 1 with ANC was expected as these were advised to avoid 
chemotherapy administration in the ipsilateral arm so were anticipated to receive all 
treatments in the same arm.  
Staff assessment of symptoms during epirubicin 
Using the Chemotherapy Induced Phlebitis Severity (CIPS) scale (Figure 1) to assess 
participants after 3 cycles of epirubicin chemotherapy there was a significant difference in 
the severity of symptoms between the arm use groups (p=<0.001).  Approximately a third of 
participants (34%), in the same arm group (37 of 108) and the mixed arm group (22 of 65) 
experienced the more severe grades 3 or 4 phlebitis compared to 6% (4 of 64) in the 
alternating arm group (Table 3) leading to an odds ratio for experiencing high grade 
symptoms of 0.12 (95% CI: 0.043- 0.38) compared to the same arm group. The odds ratio for 
most severe symptoms for the mixed arm group compared to the same arm group is 0.98 
(95% CI: 0.51 -1.88).  The alternating arm use group also demonstrated a higher proportion 
of participants who experienced no symptoms (16 of 64: 25%) compared to the same arm 
group (11 of 108: 10%) and the mixed arm use group (4 of 65: 6%).   
Participant reported symptoms during epirubicin  
The self-reported questionnaires showed that there was a significant difference between 
arm use groups, with the alternating arm group consistently reporting a lower severity of 
symptoms for all three patient reported measures than either the same arm or mixed arm 
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use groups (Table 4). The number of participants reporting severe symptoms was small so 
moderate and severe symptoms were grouped together for analysis. The alternating arm 
group reported significantly less pain (p = 0.013), significantly lower levels of overall impact 
(p = 0.009) and significantly lower effect on function (p = 0.032).     
Dose of epirubicin  
Analysis of the severity of symptoms experienced for all participants by epirubicin dose 
demonstrated that there was a significantly higher proportion of grade 3 and 4 symptoms in 
those who received 100mg/m2 (p=0.023) compared to those receiving lower doses (Table 
5). A further analysis by arm use group demonstrated that the alternating arm group 
experienced less severe symptoms at all doses, with a significantly lower proportion of 
grade 3 and 4 symptoms at the lower doses (p=0.005) and at 100mg/m2 (p= 0.025).  
Combination regimen comparison  
The chemotherapy regimen administered for the first 3 cycles was a combination of 5-
fluorouracil, epirubicin and cyclophosphamide (FEC) for 93% (221 of 237) of the participants, 
and 7% (16 of 237) received the combination of epirubicin and cyclophosphamide (EC). 
There was no significant difference in the proportion of participants experiencing grade 3 
and 4 symptoms when comparing those who had received FEC with those who had received 
EC (p=0.249). An additional analysis by arm use group for the 221 participants who had 
received FEC demonstrated that the alternating arm group experienced significantly less 
grade 3 and 4 symptoms than the other arm use groups (p=0.01).           
Symptoms after completion of epirubicin chemotherapy.  
Participants with any symptoms on completion were followed up either until the symptoms 
resolved, or for a maximum of 6 months. Complete follow up data using participant 
questionnaires to self-report symptoms were recorded for 73% (172 of 237) participants 
(Figure 2). There was a significant difference between arm use groups when comparing how 
long participants experienced symptoms after completion of chemotherapy (p=0.001). The 
alternating arm group had a significantly higher proportion completing the study with no 
symptoms requiring follow up (17 of 41: 41%) and a lower proportion still reporting 
symptoms after the maximum 6 months follow up (3 of 41: 7%) compared with the other 
groups. There was no significant difference between the same arm and mixed arms use 
groups.   
 
Discussion: 
Guidelines for administration of intravenous medication (RCN, 2016) recommend that 
central venous catheters (CVC) should be considered for the administration of drugs such as 
epirubicin with a low pH (<5) which are thought to have an increased potential for causing 
chemical phlebitis. However, the evidence base for this guidance has been questioned by 
Gorski et al (2015) who concluded that the pH of the drug cannot be used in isolation as 
basis for using a CVC.   Yamada et al (2012) in their study of epirubicin-induced vascular 
injury also state that the mechanism of epirubicin-induced phlebitis is not definitely pH 
related. The proactive placement of CVCs for epirubicin chemotherapy is reported as 
common practice in the US (Marshall-Mckenna et al, 2015) but is not routine practice in 
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many areas of the UK. Harrold et al (2015) reported on a decision in one UK oncology centre 
to place peripherally inserted central catheters (PICC) for all breast cancer patients being 
treated with anthracycline chemotherapy (including epirubicin) but acknowledged that they 
were unable to identify any national recognised best practice guidelines to support this. Le 
Vasseur et al (2018) also identified concerns at the lack of consensus for best practice, and 
the absence of research directly comparing peripheral and central venous access for 
chemotherapy administration in breast cancer.   
After 3 cycles of epirubicin 87% (206 of 237) of participants experienced phlebitis of any 
grade, however only 27% (63 of 237) experienced grade 3 and 4 symptoms which result in 
pain and interfere with arm function. The lower grade symptoms were viewed by 
participants as being a minor inconvenience and did not require clinical intervention. 
Elsewhere the reported incidence of epirubicin- induced phlebitis varies considerably; 
Nagata et al (2012) reported rates as low as 15% in 26 patients following a change in 
administration technique and formulation of epirubicin which is lower than the total rate of 
phlebitis of 87% in this study. Our reported rate is similar to the 89% reported by Lennan et 
al (2005) in their audit of 19 patients, and the incidence of up to 71% in the retrospective 
audit of 110 patients conducted by Marshall-McKenna et al (2015). It is difficult however to 
make any meaningful comparisons with the study data due to differences in methodology, 
small scale studies and use of retrospective data collection.  
A potentially confounding factor in this study was the inclusion of participants who had 
received different combination regimens, 7% (16 of 237) received combination 
chemotherapy without 5- fluorouracil (5-FU). The chemotherapy drug 5-FU is also known to 
cause phlebitis and could have potentially influenced the incidence and severity of  phlebitis 
however the phlebitis resulting from 5-FU is most commonly seen with prolonged infusions 
rather than the bolus administration used for this study (Gebbia et al 1999) and although 5-
FU is a venous irritant it is usually associated with superficial phlebitis symptoms (Berardi et 
al 2003) without the more severe venous sclerosis resulting from the vesicant epirubicin.  
Zhang et al (2016) demonstrated that the incidence of phlebitis was significantly lower when 
epirubicin and cyclophosphamide were given in combination with capecitabine (an oral pro-
drug of 5-FU) instead of intravenous 5-FU. However, the TACT-2 study with over 4,000 
participants (Cameron et al 2017) demonstrated no significant difference in the rates of 
phlebitis when comparing the combination of intravenous cyclophosphamide, methotrexate 
and 5FU with oral capecitabine (both administered after four cycles of epirubicin). The 
results of our study support the findings of Cameron et al (2017) with no significant 
difference in the severity of phlebitis (p=0.249) between those receiving epirubicin in 
combination with 5-FU and compared to those who did not receive 5-FU.    
Using a CVC could potentially have prevented the distressing higher-grade symptoms 
experienced by 27% of our participants. However, as we were unable to predict who will 
experience the higher-grade symptoms the routine use of CVC would have resulted in 73% 
(174 of 237) of participants who experienced no or low-grade symptoms undergoing the 
placement of a CVC for no clear clinical benefit. CVCs are associated with an increased risk 
of infection and thrombosis (Beckers et al, 2010), along with the potential for delay in 
commencing treatment, increased costs of placement and follow up care. Therefore, there 
should be a clear evidence-based rationale for the decision to place a CVC, particularly for 
patients receiving chemotherapy who are at an increased risk of potentially life-threatening 
infection and thrombosis (Noble and Pasi, 2010).  
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Uslusoy and Mete (2008) identified that rates of phlebitis are higher when repeatedly using 
the same arm for intravenous medication, and alternating arm administration is 
recommended as best practice to preserve veins for prolonged courses of intravenous 
therapy (Weinstein, 2007). However, for many years patients with breast cancer have 
received all chemotherapy treatments in the contralateral arm, increasing the risk of 
significant phlebitis and venous sclerosis. The advice to avoid all medical procedures in the 
arm on the side of breast surgery including venepuncture, cannulation and even blood 
pressure monitoring has arisen from concerns about increasing the risk of developing 
lymphoedema. The evidence base for this practice is poor and has even been described as 
anecdotal (Ferguson et al, 2016). The most recent guidance from National Institute for 
Health and Care Excellence guidance (NICE, 2018) confirms the lack of evidence for any 
increased risk of lymphoedema following medical procedures including injections on the 
surgical arm and advices that decisions about using the ipsilateral arm should be made 
depending on clinical need.  
Our study demonstrates that alternating arm use is associated with a significant reduction in 
the proportion of participants experiencing severe symptoms of chemical phlebitis.  Severe 
grade 3 and 4 symptoms were experienced in only 6% of those using alternating arms 
compared to 34% in the two other arm use groups (p = <0.001). There was a clearly 
observed association between the dose of epirubicin and the severity of symptoms with a 
higher incidence of grade 3 and 4 symptoms for those who received higher doses of 
epirubicin (p=0.023). However alternating arm use resulted in a significantly lower incidence 
of high-grade symptoms at doses of 100mg/m2 with 10% of the alternating arm group 
experiencing grade 3 or 4 symptoms compared to 42% in the same arm group, and 45% in 
the mixed arm use group (p= 0.025). These results indicate that peripheral administration of 
epirubicin chemotherapy can be safely delivered even at higher doses if alternating arms are 
used. However, it is recommended that a CVC should be considered for patients receiving 
doses of 100mg/m2 where alternating arms cannot be used, or who have poor venous 
access. In our study alternating arms for chemotherapy administration was recommended 
only for patients who had not undergone a full axillary node clearance. The 2018 NICE 
guidance advises that patients should be informed that there is no additional risk of 
lymphoedema if the ipsilateral arm is used for intravenous drug administration and does not 
distinguish between ANC and SNB. Therefore, consideration should also be given to offering 
the choice of alternating arms to all women with breast cancer including following an ANC, 
this could further reduce the need for CVC placement.  
There was no difference in the proportion of participants experiencing severe symptoms 
between the same arm group and mixed arm group. This would suggest that the 
administration of at least two consecutive cycles in the same arm is a key factor in the 
development of higher-grade phlebitis. Participants in the alternating arm group frequently 
reported a delayed onset of symptoms which occurred approximately five weeks after 
chemotherapy was last administered. Webster et al (2015) identified that phlebitis results 
from an inflammatory response and therefore symptoms of post-infusion phlebitis 
commonly present late. Hegerova et al (2015) also reported a delayed onset of phlebitis 
following doxorubicin chemotherapy with symptoms appearing on average 22 days after 
treatment.  There is thus a cumulative effect with increased venous irritation and higher-
grade symptoms occurring when consecutive cycles are administered in the same arm. This 
can be seen with the increasing severity of symptoms from cycle 1 to 3 with only two 
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participants (1%) experiencing higher grade symptoms after cycle 1 compared to 54 (23%) 
after cycle 3.  
It was observed that many of the participants in the mixed arm group (Group 3) chose to 
swap to the alternate arm for cycle 3 after two consecutive cycles in the same arm had 
resulted in developing more severe symptoms. This reflects the initial reluctance of both 
staff and patients to change practice due to historical concerns about the risk of 
lymphoedema. It was noted that the proportion of participants who had not undergone 
ANC who received chemotherapy in alternating arms increased from 25% in the first 6 
months of recruitment to 65% in the final 6 months. This demonstrates the time taken for 
this change to be embedded in practice, acceptance of the recommendations required 
consistent information and explanation to both staff and patients. However there remains 
some resistance to the change reflecting how deeply engrained the beliefs about 
lymphoedema risk are, despite the lack of evidence.  
No recommendations were made concerning the sequence of arm use, however it was 
interesting to note that in the alternating arm group 90% (35 of 39) of those who had 
undergone breast surgery received only 1 cycle in the surgical arm, and 65% (13 of 20) of 
those undergoing neo-adjuvant chemotherapy received only 1 cycle in the arm on the side 
affected. This would suggest a deliberate choice to use the ipsilateral arm only once. It is not 
known if this was a result of patient choice, guidance from the clinical team or a 
combination of factors.  
There was also a significant difference in the duration of symptoms reported by participants 
after completion of epirubicin chemotherapy with approximately a third of the same arm 
and mixed arm use groups still reporting symptoms 6 months after completion of treatment 
compared to 10% of the alternating arm group (p=0.001). Participant comments reflected 
the considerable negative impact of ongoing symptoms of pain and arm tightness on their 
daily activities and how the visible scarring of veins affected their body image (Figure 3).   
Study Limitations 
This study was undertaken for patients under the care of one UK Cancer Centre it was an 
observational study, neither blinded or randomised for arm use. Data analysis was based on 
3 cycles as the number of participants completing 6 cycles was small (not reported). The 
follow up survey of phlebitis symptoms were self-reported and thus are likely to be more 
variable than those reported by staff.  
Conclusion:   
Peripheral cannulation which is inexpensive, minimally invasive and does not require any 
ongoing care remains the primary venous access choice for many areas for epirubicin 
administration despite the risk of chemical phlebitis. There is therefore a need to identify 
who is most at risk of epirubicin- induced phlebitis and whether administration techniques 
can reduce the incidence. Although intravenous access guidance suggests that irritant drugs 
such as epirubicin should be ideally administered through a central line, 73% of participants 
in this study did not experience significant symptoms and where alternating arms were used 
this number increased to 94%. This study has clearly demonstrated that women with breast 
cancer who used alternating arms for peripheral administration of epirubicin experienced a 
significant reduction in severity and duration of chemical phlebitis.  
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Decisions about venous access choices should be made after an informed discussion with 
the patient based on evidence. This study has helped to provide evidence to inform 
discussions with patients when making choices about venous access for epirubicin 
chemotherapy. However more studies are required for a better understanding of the risk 
factors for epirubicin-induced phlebitis to enable a fully informed discussion with patients 
about their individual risk and whether they would benefit from a CVC.  
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Tables 
Table 1: Combination chemotherapy regimens including epirubicin used to treat participants  
Regimen  Drugs  Dose Usual number 
of cycles  
Number of 
participants  
FEC 5 Fluorouracil 
Epirubicin  
Cyclophosphamide  
600mg/m2 
60 or 75mg/m2 
600mg/m2 
6 cycles 56  
FEC -T  5 Fluorouracil 
Epirubicin  
Cyclophosphamide 
Docetaxel (Taxotere™) 
600mg/m2 
60, 75 or 100mg/m2 
600mg/m2 
75mg/m2 
3 cycles FEC  
folllowed by  
3 cycles 
Docetaxel  
165  
EC  Epirubicin  
Cyclophosphamide 
60, 75 or 100mg/m2 
600mg/m2 
4 or 6 cycles  16  
 
Table 2: Key patient and treatment characteristics by arm use group 
  Group 1: n= 108 
Same arm    
Group 2: n= 64 
Alternating arms 
Group 3: n= 65 
Mixed arms                 
Age (years)# 55 ± 10 55 ± 12 51 ± 12 
BMI# 29 ± 6 29 ± 6 29 ± 6 
Smoking 
history  
Never smoked  59 (55%) 39 (61%) 36 (55%) 
Previous smoker  35 (32%) 20 (31%) 24 (37%) 
Current smoker  14 (13%) 5 (8%) 5 (8%) 
Axillary 
surgery  
None  1 (1%) 22 (34%) * 21 (32%) 
Sentinel node 
biopsy (SNB) 
20 (19%) 39 (61%) * 43 (66%) 
Axillary node 
clearance (ANC)  
87 (81%) 3 (5%) * 1 (2%) 
Baseline 
albumin g/l  
< 35 9 (8%) 5 (8%) 7 (11%) 
≥ 35 99 (92%) 59 (92%) 58 (89%) 
Epirubicin 
dose mg/m2 
60  2 (2%) 2 (3%) 1 (2%) 
75  63 (58%) 42 (66%) 42 (65%) 
100  43 (40%) 20 (31%) 22 (34%) 
Ethnic group  White  96 (89%) 59 (92%) 59 (92%) 
Non-white  8 (7%) 2 (3%) 2 (3%) 
Missing data 4 (4%) 3 (5%) 4 (6%) 
#Mean ± SD shown. See text for groups. * p =< 0.05 2 test: Group 2 compared to Groups 
1&3, otherwise no significant differences were observed between groups. 
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Table 3: Graded severity of symptoms in each arm use group after 3 cycles of epirubicin 
chemotherapy. 
 Group 1: n= 108 
Same arm 
Group 2: n= 64 
Alternating arms 
Group 3: n= 65 
Mixed arms 
Grade 0:  n (%) 11 (10) 16 (25) * 4 (6) 
Grade 1&2: n (%) 60 (56) 44 (69) 39 (60) 
Grade 3&4: n (%)  37 (34) 4 (6) *  22 (34)  
* p =< 0.05 2 test: Group 2 compared to Groups 1&3, otherwise no significant differences 
were observed between groups. 
Table 4; Participant reported symptoms after 3 cycles of epirubicin 
 Group 1: n= 108 
Same arm 
Group 2: n= 64 
Alternating arms 
Group 3: n= 65 
Mixed arms 
 
Pain: n (%) 
None 17 (16)  21 (33) * 10 (15) 
Mild  43 (40) 27 (42) 23 (35) 
Moderate + 
severe 
36+9 (42) 14+1 (23) * 25 +7 (49)  
Missing  3 (3) 1 (2) 0 
 
Overall 
impact: n (%) 
None 51 (47) 48 (75) * 34 (52) 
Mild  29 (27) 11 (17) 20 (31) 
Moderate + 
severe  
24+1 (23) 5+0 (8) * 11+0 (17) 
Missing  3 (3) 0 0 
 
Effect on arm 
function: n (%)  
None 61 (56) 50 (78) * 38 (58) 
Mild  30 (28) 13 (20) 18 (28) 
Moderate + 
severe  
14+0 (13) 1+0 (2) * 8+0 (12) 
Missing  3 (3) 0 0 
* p =< 0.05 2 test: Group 2 compared to Groups 1&3, otherwise no significant differences 
were observed between groups. 
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Table 5: Symptom grade by arm use group and dose of epirubicin 
* p =< 0.05 2 test: Group 2 compared to Groups 1&3, otherwise no significant differences 
were observed between groups. 
 
Inclusion criteria Exclusion criteria  
 Breast cancer diagnosis – primary, 
secondary or recurrence  
 Age 18 years or over  
 Female  
 Planned to receive anthracycline 
chemotherapy  
 Chemotherapy planned to be given via 
a peripheral venous cannula  
 Assessed as medically fit to receive 
anthracycline based chemotherapy  
 Pregnant  
 Male  
 Under 18 years old  
 Unable to provide informed consent  
 For chemotherapy not including an 
anthracycline  
 Chemotherapy planned to be given 
through a central venous catheter 
 Assessed as not medically fit for 
anthracycline chemotherapy.  
Table 6: inclusion and exclusion criteria  
 
 
 
 
 
 
 
 
 60 & 75mg/m2 (n=152)  100mg/m2 (n= 85)  
Grades 
0,1 & 2 
Grades 
3 & 4 
Grades 
0,1 & 2 
Grades 
3 & 4 
Group 1: 
Same arm      
(n= 65) 
46 (71%) 19 (29%) Group 1:  
Same arm 
(n=43) 
25 (58%) 
 
18 (42%) 
Group 2: 
Alternate arms 
(n=44) 
42 (95%) * 2 (5%) * Group 2:  
Alternate arms 
(n=20) 
18 (90%) * 
 
2 (10%) * 
Group 3: 
Mixed arms 
(n=43)  
31 (72%)  12 (28%) Group 3: 
Mixed arms 
(n=22) 
12 (55%) 10 (45%) 
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Figures  
 
Figure 1; Chemotherapy Induced Phlebitis Severity scale (CIPS) 
17 
 
 
Figure 2: Proportion of participants reporting symptoms during follow up 
___ Group 1: same arm;  -----  Group 2: alternate arms;  ……. Group 3: mixed arms.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3:  Participant comments reflecting the impact of symptoms post chemotherapy 
